Posts in tag

PBAC


PBAC recommends expanding empagliflozin treatment population in line with “pivotal” trial, changes to max quantities for pioglitazone and listing of new contraceptive choice in May meeting The PBAC has recommended …

NIP listing proposal for immunising infants and young children temporarily knocked back for legislative reasons A decision on the proposed NIP listing of respiratory syncytial virus (RSV) vaccine nirsevimab (Beyfortus) …

PBAC recommends new PBS listings for oral contraception plus treatment of atopic dermatitis and severe asthma in children The PBAC has recommended listing estetrol with drospirenone (Nextstellis) on the PBS …

Recent supply shortages for first-line migraine meds hit patients hard and increased workloads, according to a PBAC stakeholder meeting Calcitonin gene-related peptide (CRGP) therapies are recommended as first-line medications for …

High volume of submissions prompts government to add extra Pharmaceutical Benefits Advisory Committee meeting in 2025  The Pharmaceutical Benefits Advisory Committee (PBAC) will hold an additional full meeting in May …

Endometriosis, OCP drug listings recommended to increase access and multiple treatment options for women The PBAC has recommended unrestricted benefit listings of drospirenone with ethinylestradiol (Yaz and Yasmin) oral contraceptive …

Chronic pain patients who are struggling to cover the costs of medicinal cannabis treatments are being urged to talk to their pharmacists  Legislation requiring medications to be approved by the …

PBAC recommends PBS listing of drug to treat endometriosis pain, noting need for new treatments for the condition The PBAC has recommended PBS listing of Ryeqo for treatment of moderate …

Outgoing MSAC chair, Professor Robyn Ward, will take on the leadership of the PBAC this May  Professor Ward, the executive dean of the Faculty of Medicine and Health at the …

Government extends Safety Net early supply rule for 60-day scripts to reduce medicines wastage  Changes to the Pharmaceutical Benefits Scheme (PBS) Safety Net early supply rule come into effect today …

Eli Lilly’s Mounjaro would need “substantial price reduction”, says PBAC Mounjaro, the type-2 diabetes medication that the New York Times recently predicted “’could overshadow Ozempic” has been refused funding via …

Community pharmacists are being urged to “keep the pressure on the government” to limit the adverse impacts of 60-day dispensing  Government officials need to restart negotiations with community pharmacy leaders …